| Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer TW Miller, BT Hennessy, AM González-Angulo, EM Fox, GB Mills, H Chen, ... The Journal of clinical investigation 120 (7), 2406-2413, 2010 | 595 | 2010 |
| Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer TW Miller, BN Rexer, JT Garrett, CL Arteaga Breast cancer research 13, 1-12, 2011 | 549 | 2011 |
| Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer TW Miller, JM Balko, CL Arteaga Journal of clinical oncology 29 (33), 4452, 2011 | 459 | 2011 |
| ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer TW Miller, JM Balko, EM Fox, Z Ghazoui, A Dunbier, H Anderson, ... Cancer discovery 1 (4), 338-351, 2011 | 357 | 2011 |
| Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance JM Balko, RS Cook, DB Vaught, MG Kuba, TW Miller, NE Bhola, ... Nature medicine 18 (7), 1052-1059, 2012 | 309 | 2012 |
| Therapeutic targeting of cancers with loss of PTEN function L M Dillon, T W Miller Current drug targets 15 (1), 65-79, 2014 | 274 | 2014 |
| Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast … TW Miller, M Pérez-Torres, A Narasanna, M Guix, O Stål, ... Cancer research 69 (10), 4192-4201, 2009 | 198 | 2009 |
| A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer EM Fox, TW Miller, JM Balko, MG Kuba, V Sánchez, RA Smith, S Liu, ... Cancer research 71 (21), 6773-6784, 2011 | 184 | 2011 |
| Biomarkers of response to Akt inhibitor MK-2206 in breast cancer T Sangai, A Akcakanat, H Chen, E Tarco, Y Wu, KA Do, TW Miller, ... Clinical Cancer Research 18 (20), 5816-5828, 2012 | 177 | 2012 |
| Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies WJ Wolfgang, TW Miller, JM Webster, JS Huston, LM Thompson, ... Proceedings of the National Academy of Sciences 102 (32), 11563-11568, 2005 | 175 | 2005 |
| Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways SR Hosford, TW Miller Pharmacogenomics and personalized medicine, 203-215, 2014 | 167 | 2014 |
| Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer JM Balko, LJ Schwarz, NE Bhola, R Kurupi, P Owens, TW Miller, H Gómez, ... Cancer research 73 (20), 6346-6358, 2013 | 159 | 2013 |
| Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells TW Miller, JT Forbes, C Shah, SK Wyatt, HC Manning, MG Olivares, ... Clinical Cancer Research 15 (23), 7266-7276, 2009 | 140 | 2009 |
| A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance TW Miller, JM Balko, Z Ghazoui, A Dunbier, H Anderson, M Dowsett, ... Clinical Cancer Research 17 (7), 2024-2034, 2011 | 119 | 2011 |
| Statistical determination of synergy based on Bliss definition of drugs independence E Demidenko, TW Miller PLoS One 14 (11), e0224137, 2019 | 105 | 2019 |
| Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation EM Fox, MG Kuba, TW Miller, BR Davies, CL Arteaga Breast Cancer Research 15, 1-14, 2013 | 105 | 2013 |
| Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer C Shah, TW Miller, SK Wyatt, ET McKinley, MG Olivares, V Sanchez, ... Clinical Cancer Research 15 (14), 4712-4721, 2009 | 102 | 2009 |
| Intrabody applications in neurological disorders: progress and future prospects TW Miller, A Messer Molecular Therapy 12 (3), 394-401, 2005 | 102 | 2005 |
| Implementation of a molecular tumor board: the impact on treatment decisions for 35 patients evaluated at Dartmouth-Hitchcock Medical Center LJ Tafe, IP Gorlov, FB De Abreu, JA Lefferts, X Liu, JR Pettus, JD Marotti, ... The oncologist 20 (9), 1011-1018, 2015 | 89 | 2015 |
| P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer LM Dillon, JR Bean, W Yang, K Shee, LK Symonds, JM Balko, ... Oncogene 34 (30), 3968-3976, 2015 | 84 | 2015 |
